Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J, trade group press FDA on sunscreen monograph

This article was originally published in The Tan Sheet

Executive Summary

The Personal Care Products Council requests a meeting with FDA to discuss the sunscreen ingredient monograph proposed in 2007. In a Nov. 3 1letter to Principal Deputy Commissioner Josh Sharfstein, the council urges the agency "to finalize the sunscreen regulations in a way that allows for labeling that educates and helps consumers protect themselves from the dangers of sun exposure." A council spokeswoman said the trade group has not heard back from FDA. Johnson & Johnson and its subsidiary Neutrogena sent a subsequent 2letter Nov. 5 voicing the company's concerns about the monograph's proposal to cap sunscreen label claims at SPF 50, unless adequate supporting data are submitted (3"The Tan Sheet" Aug. 27, 2007). "Any proposed cap on SPF labeling is not necessary and will significantly contribute to reduced innovation and likely reduced communication spends within our industry," J&J says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel